000274576 001__ 274576
000274576 005__ 20240229154936.0
000274576 0247_ $$2doi$$a10.3390/cancers15061660
000274576 0247_ $$2pmid$$apmid:36980545
000274576 0247_ $$2pmc$$apmc:PMC10046156
000274576 0247_ $$2altmetric$$aaltmetric:144580296
000274576 037__ $$aDKFZ-2023-00653
000274576 041__ $$aEnglish
000274576 082__ $$a610
000274576 1001_ $$aHoppe, Bradford S$$b0
000274576 245__ $$aPragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design.
000274576 260__ $$aBasel$$bMDPI$$c2023
000274576 3367_ $$2DRIVER$$aarticle
000274576 3367_ $$2DataCite$$aOutput Types/Journal article
000274576 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1680511769_22930
000274576 3367_ $$2BibTeX$$aARTICLE
000274576 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274576 3367_ $$00$$2EndNote$$aJournal Article
000274576 520__ $$aSurgical treatment of pelvic sarcoma involving the bone is the standard of care but is associated with several sequelae and reduced functional quality of life (QOL). Treatment with photon and proton radiotherapy is associated with relapse. Carbon ion radiotherapy (CIRT) may reduce both relapse rates and treatment sequelae. The PROSPER study is a tricontinental, nonrandomized, prospective, three-arm, pragmatic trial evaluating treatments of pelvic sarcoma involving the bone. Patients aged at least 15 years are eligible for inclusion. Participants must have an Eastern Cooperative Oncology Group Performance Status score of two or less, newly diagnosed disease, and histopathologic confirmation of pelvic chordoma, chondrosarcoma, osteosarcoma, Ewing sarcoma with bone involvement, rhabdomyosarcoma (RMS) with bone involvement, or non-RMS soft tissue sarcoma with bone involvement. Treatment arms include (1) CIRT (n = 30) delivered in Europe and Asia, (2) surgical treatment with or without adjuvant radiotherapy (n = 30), and (3) proton therapy (n = 30). Arms two and three will be conducted at Mayo Clinic campuses in Arizona, Florida, and Minnesota. The primary end point is to compare the 1-year change in functional QOL between CIRT and surgical treatment. Additional comparisons among the three arms will be made between treatment sequelae, local control, and other QOL measures.
000274576 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000274576 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000274576 650_7 $$2Other$$acancer treatment
000274576 650_7 $$2Other$$acarbon ion
000274576 650_7 $$2Other$$aclinical trial
000274576 650_7 $$2Other$$apelvic sarcoma
000274576 650_7 $$2Other$$aproton therapy
000274576 650_7 $$2Other$$aradiotherapy
000274576 650_7 $$2Other$$asurgical treatment
000274576 7001_ $$aPetersen, Ivy A$$b1
000274576 7001_ $$aWilke, Benjamin K$$b2
000274576 7001_ $$aDeWees, Todd A$$b3
000274576 7001_ $$00000-0002-4535-3673$$aImai, Reiko$$b4
000274576 7001_ $$aHug, Eugen B$$b5
000274576 7001_ $$aFiore, Maria Rosaria$$b6
000274576 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b7$$udkfz
000274576 7001_ $$aFossati, Piero$$b8
000274576 7001_ $$00000-0002-4271-0209$$aYamada, Shigeru$$b9
000274576 7001_ $$aOrlandi, Ester$$b10
000274576 7001_ $$aZhang, Qing$$b11
000274576 7001_ $$aBao, Cihang$$b12
000274576 7001_ $$0P:(DE-HGF)0$$aSeidensaal, Katharina$$b13
000274576 7001_ $$00000-0002-8514-1878$$aMay, Byron C$$b14
000274576 7001_ $$00009-0007-5345-8006$$aHarrell, Anna C$$b15
000274576 7001_ $$00000-0003-0390-1018$$aHoudek, Matthew T$$b16
000274576 7001_ $$aVallow, Laura A$$b17
000274576 7001_ $$aRose, Peter S$$b18
000274576 7001_ $$aHaddock, Michael G$$b19
000274576 7001_ $$aAshman, Jonathan B$$b20
000274576 7001_ $$aGoulding, Krista A$$b21
000274576 7001_ $$aAttia, Steven$$b22
000274576 7001_ $$00000-0002-1340-4771$$aKrishnan, Sunil$$b23
000274576 7001_ $$aMahajan, Anita$$b24
000274576 7001_ $$00000-0003-3470-6872$$aFoote, Robert L$$b25
000274576 7001_ $$aLaack, Nadia N$$b26
000274576 7001_ $$aKeole, Sameer R$$b27
000274576 7001_ $$aBeltran, Chris J$$b28
000274576 7001_ $$aWelch, Eric M$$b29
000274576 7001_ $$aKarim, Mohammed$$b30
000274576 7001_ $$aAhmed, Safia K$$b31
000274576 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers15061660$$gVol. 15, no. 6, p. 1660 -$$n6$$p1660$$tCancers$$v15$$x2072-6694$$y2023
000274576 909CO $$ooai:inrepo02.dkfz.de:274576$$pVDB
000274576 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000274576 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000274576 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000274576 9141_ $$y2023
000274576 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-24T07:56:58Z
000274576 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000274576 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000274576 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000274576 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000274576 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000274576 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000274576 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000274576 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000274576 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000274576 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000274576 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000274576 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000274576 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000274576 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000274576 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000274576 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000274576 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000274576 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000274576 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000274576 980__ $$ajournal
000274576 980__ $$aVDB
000274576 980__ $$aI:(DE-He78)E050-20160331
000274576 980__ $$aUNRESTRICTED